

IN THE CLAIMS:

PEST AVAILABLE COPY

Without prejudice amend claims 27 and 32 as follows:

C1
27. (Amended) The transdermal therapeutic system of claim 26 wherein the matrix layer comprises a polyacrylate, silicone, polyisobutylene, rubber, natural or synthetic rubber, butyl rubber, styrene/isoprene copolymer, a polyurethane, a copolymer of ethylene, a polysiloxane or a styrene/butadiene copolymer.

C3
31. (Amended) The transdermal therapeutic system of claim 30 wherein the permeation promoter is selected from the group consisting of monohydric and/or polyhydric aliphatic, cycloaliphatic and/or aromatic-aliphatic alcohols each with up to 8 C atoms, and/or polyethylene glycol; an alcohol/water mixture; saturated and/or unsaturated fatty alcohols each with 8-18 C atoms; a terpene; a mixture of a terpene and ethanol and/or propylene glycol; tea tree oil; a saturated and/or unsaturated cyclic ketone; an alkyl methyl sulfoxide; saturated and/or unsaturated fatty acids each with 8-18 C atoms, the esters and salts thereof; natural vitamin E; synthetic vitamin E and/or a vitamin E derivative; sorbitan fatty acid esters and ethoxylated sorbitan fatty acid esters; Azone (laurocapram); Azone mixed with an alcohol; urea; 1-alkylpyrrolidone; block copolymers of polyethylene glycol and dimethylsiloxane with cationic groups at one end; folate-polyethylene glycol liposome, proliposome; polyoxyethylene 10 stearyl ether; a mixture of polyoxyethylene 10 stearyl ether and glycetyl dilaurate; dodecyl 2-(N,N-dimethylamino)propanoltetradecanoate and/or dodecyl 2-(N,N-dimethylamino)propionateN-acetylprolinate esters with more than 8 C atoms; nonionic surfactants, esters of polyoxyethylene; ethosome (phospholipid vesicle); dimethyl(arylimino)sulfurane; a mixture of an oleic acid analog and propylene glycol; a mixture of padimate O, octyl salicylate, octyl methoxycinnamate and laurocapram and/or mixtures thereof.